China’s Ascletis reported phase 2 topline data from a U.S. study of ASC30, showing placebo‑adjusted weight reductions of 5.4%, 7.0% and 7.7% at 13 weeks across three dose cohorts; the highest dose produced the largest effect. The company said adverse events were mostly grade 1–2 and that vomiting was lower than rates reported with some other oral small‑molecule GLP‑1s when titrated weekly. Ascletis’ numbers place it in the middle of the growing oral obesity field and provide a dataset for partners or acquirers weighing U.S. development. Cross‑trial comparisons remain limited because of differences in duration and trial size; longer follow‑up will be needed to map durability versus established peptide therapies and rival small molecules.